Advances in drug design based on the amino acid approach: Taurine analogues for the treatment of CNS diseases

Detalhes bibliográficos
Autor(a) principal: Chung, Man Chin [UNESP]
Data de Publicação: 2012
Outros Autores: Malatesta, Pedro [UNESP], Bosquesi, Priscila Longhin [UNESP], Yamasaki, Paulo Renato [UNESP], dos Santos, Jean Leandro [UNESP], Vizioli, Ednir Oliveira [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.3390/ph5101128
http://hdl.handle.net/11449/73673
Resumo: Amino acids are well known to be an important class of compounds for the maintenance of body homeostasis and their deficit, even for the polar neuroactive aminoacids, can be controlled by supplementation. However, for the amino acid taurine (2-aminoethanesulfonic acid) this is not true. Due its special physicochemical properties, taurine is unable to cross the blood-brain barrier. In addition of injured taurine transport systems under pathological conditions, CNS supplementation of taurine is almost null. Taurine is a potent antioxidant and anti-inflammatory semi-essential amino acid extensively involved in neurological activities, acting as neurotrophic factor, binding to GABA A/glycine receptors and blocking the excitotoxicity glutamate-induced pathway leading to be a neuroprotective effect and neuromodulation. Taurine deficits have been implicated in several CNS diseases, such as Alzheimer's, Parkinson's, epilepsy and in the damage of retinal neurons. This review describes the CNS physiological functions of taurine and the development of new derivatives based on its structure useful in CNS disease treatment.&; 2012 by the authors; licensee MDPI, Basel, Switzerland.
id UNSP_4866b0105bd997c8212cd4441c24ae89
oai_identifier_str oai:repositorio.unesp.br:11449/73673
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Advances in drug design based on the amino acid approach: Taurine analogues for the treatment of CNS diseasesAmino acidAnalogsCNSTaurine2 aminoethylmethylsulfone2 aminoethylphosphonic acid2 phthalimidoethanesulfonamide derivative4 aminobutyric acid A receptoracamprosatealcoholaminocyclohexaenesulfonic acidaniline 2 sulfinic acidanticonvulsive agentcysteic aciddimethyltaurineethanolamine sulfateglutaurineglycine receptorhomotaurinen methyl thiomorpholine 1,1 dioxiden pivaloyltaurinepiperidine 3 sulfinic acidtau 15taurepartaurinetaurine derivativetaurocholic acidtaurolidinetauropyronethiomorpholine 1,1 dioxidetrimethyltaurineunclassified drugvalproyltaurinamide derivativealcoholismAlzheimer diseaseamino acid substitutionanticonvulsant activitybipolar disorderblood brain barrierbrain edemabrain ischemiacentral nervous system diseasecentral nervous system tumorCLogPdigestive system cancerdose responsedrug designdrug efficacydrug potencydrug receptor bindingdrug structuredrug synthesisexcitotoxicityhumanhyperthermiahypothermialipophilicitylow drug doseneuromodulationneuroprotectionnonhumanParkinson diseaseretina diseasereviewseizurespinal cord compressionstatistical parametersstructure activity relationtoxicity testingAmino acids are well known to be an important class of compounds for the maintenance of body homeostasis and their deficit, even for the polar neuroactive aminoacids, can be controlled by supplementation. However, for the amino acid taurine (2-aminoethanesulfonic acid) this is not true. Due its special physicochemical properties, taurine is unable to cross the blood-brain barrier. In addition of injured taurine transport systems under pathological conditions, CNS supplementation of taurine is almost null. Taurine is a potent antioxidant and anti-inflammatory semi-essential amino acid extensively involved in neurological activities, acting as neurotrophic factor, binding to GABA A/glycine receptors and blocking the excitotoxicity glutamate-induced pathway leading to be a neuroprotective effect and neuromodulation. Taurine deficits have been implicated in several CNS diseases, such as Alzheimer's, Parkinson's, epilepsy and in the damage of retinal neurons. This review describes the CNS physiological functions of taurine and the development of new derivatives based on its structure useful in CNS disease treatment.&; 2012 by the authors; licensee MDPI, Basel, Switzerland.Lapdesf-Laboratory of Drug Design School of Pharmaceutical Sciences University of São Paulo State (UNESP), Rodovia Araraquara-Jaú Km1, CEP 14.801-902, Araraquara, SPLapdesf-Laboratory of Drug Design School of Pharmaceutical Sciences University of São Paulo State (UNESP), Rodovia Araraquara-Jaú Km1, CEP 14.801-902, Araraquara, SPUniversidade Estadual Paulista (Unesp)Chung, Man Chin [UNESP]Malatesta, Pedro [UNESP]Bosquesi, Priscila Longhin [UNESP]Yamasaki, Paulo Renato [UNESP]dos Santos, Jean Leandro [UNESP]Vizioli, Ednir Oliveira [UNESP]2014-05-27T11:27:06Z2014-05-27T11:27:06Z2012-10-23info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1128-1146application/pdfhttp://dx.doi.org/10.3390/ph5101128Pharmaceuticals, v. 5, n. 10, p. 1128-1146, 2012.1424-8247http://hdl.handle.net/11449/7367310.3390/ph51011282-s2.0-848692066932-s2.0-84869206693.pdf97343336079754130000-0003-4141-0455Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengPharmaceuticals1,293info:eu-repo/semantics/openAccess2024-04-17T18:28:59Zoai:repositorio.unesp.br:11449/73673Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-04-17T18:28:59Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Advances in drug design based on the amino acid approach: Taurine analogues for the treatment of CNS diseases
title Advances in drug design based on the amino acid approach: Taurine analogues for the treatment of CNS diseases
spellingShingle Advances in drug design based on the amino acid approach: Taurine analogues for the treatment of CNS diseases
Chung, Man Chin [UNESP]
Amino acid
Analogs
CNS
Taurine
2 aminoethylmethylsulfone
2 aminoethylphosphonic acid
2 phthalimidoethanesulfonamide derivative
4 aminobutyric acid A receptor
acamprosate
alcohol
aminocyclohexaenesulfonic acid
aniline 2 sulfinic acid
anticonvulsive agent
cysteic acid
dimethyltaurine
ethanolamine sulfate
glutaurine
glycine receptor
homotaurine
n methyl thiomorpholine 1,1 dioxide
n pivaloyltaurine
piperidine 3 sulfinic acid
tau 15
taurepar
taurine
taurine derivative
taurocholic acid
taurolidine
tauropyrone
thiomorpholine 1,1 dioxide
trimethyltaurine
unclassified drug
valproyltaurinamide derivative
alcoholism
Alzheimer disease
amino acid substitution
anticonvulsant activity
bipolar disorder
blood brain barrier
brain edema
brain ischemia
central nervous system disease
central nervous system tumor
CLogP
digestive system cancer
dose response
drug design
drug efficacy
drug potency
drug receptor binding
drug structure
drug synthesis
excitotoxicity
human
hyperthermia
hypothermia
lipophilicity
low drug dose
neuromodulation
neuroprotection
nonhuman
Parkinson disease
retina disease
review
seizure
spinal cord compression
statistical parameters
structure activity relation
toxicity testing
title_short Advances in drug design based on the amino acid approach: Taurine analogues for the treatment of CNS diseases
title_full Advances in drug design based on the amino acid approach: Taurine analogues for the treatment of CNS diseases
title_fullStr Advances in drug design based on the amino acid approach: Taurine analogues for the treatment of CNS diseases
title_full_unstemmed Advances in drug design based on the amino acid approach: Taurine analogues for the treatment of CNS diseases
title_sort Advances in drug design based on the amino acid approach: Taurine analogues for the treatment of CNS diseases
author Chung, Man Chin [UNESP]
author_facet Chung, Man Chin [UNESP]
Malatesta, Pedro [UNESP]
Bosquesi, Priscila Longhin [UNESP]
Yamasaki, Paulo Renato [UNESP]
dos Santos, Jean Leandro [UNESP]
Vizioli, Ednir Oliveira [UNESP]
author_role author
author2 Malatesta, Pedro [UNESP]
Bosquesi, Priscila Longhin [UNESP]
Yamasaki, Paulo Renato [UNESP]
dos Santos, Jean Leandro [UNESP]
Vizioli, Ednir Oliveira [UNESP]
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (Unesp)
dc.contributor.author.fl_str_mv Chung, Man Chin [UNESP]
Malatesta, Pedro [UNESP]
Bosquesi, Priscila Longhin [UNESP]
Yamasaki, Paulo Renato [UNESP]
dos Santos, Jean Leandro [UNESP]
Vizioli, Ednir Oliveira [UNESP]
dc.subject.por.fl_str_mv Amino acid
Analogs
CNS
Taurine
2 aminoethylmethylsulfone
2 aminoethylphosphonic acid
2 phthalimidoethanesulfonamide derivative
4 aminobutyric acid A receptor
acamprosate
alcohol
aminocyclohexaenesulfonic acid
aniline 2 sulfinic acid
anticonvulsive agent
cysteic acid
dimethyltaurine
ethanolamine sulfate
glutaurine
glycine receptor
homotaurine
n methyl thiomorpholine 1,1 dioxide
n pivaloyltaurine
piperidine 3 sulfinic acid
tau 15
taurepar
taurine
taurine derivative
taurocholic acid
taurolidine
tauropyrone
thiomorpholine 1,1 dioxide
trimethyltaurine
unclassified drug
valproyltaurinamide derivative
alcoholism
Alzheimer disease
amino acid substitution
anticonvulsant activity
bipolar disorder
blood brain barrier
brain edema
brain ischemia
central nervous system disease
central nervous system tumor
CLogP
digestive system cancer
dose response
drug design
drug efficacy
drug potency
drug receptor binding
drug structure
drug synthesis
excitotoxicity
human
hyperthermia
hypothermia
lipophilicity
low drug dose
neuromodulation
neuroprotection
nonhuman
Parkinson disease
retina disease
review
seizure
spinal cord compression
statistical parameters
structure activity relation
toxicity testing
topic Amino acid
Analogs
CNS
Taurine
2 aminoethylmethylsulfone
2 aminoethylphosphonic acid
2 phthalimidoethanesulfonamide derivative
4 aminobutyric acid A receptor
acamprosate
alcohol
aminocyclohexaenesulfonic acid
aniline 2 sulfinic acid
anticonvulsive agent
cysteic acid
dimethyltaurine
ethanolamine sulfate
glutaurine
glycine receptor
homotaurine
n methyl thiomorpholine 1,1 dioxide
n pivaloyltaurine
piperidine 3 sulfinic acid
tau 15
taurepar
taurine
taurine derivative
taurocholic acid
taurolidine
tauropyrone
thiomorpholine 1,1 dioxide
trimethyltaurine
unclassified drug
valproyltaurinamide derivative
alcoholism
Alzheimer disease
amino acid substitution
anticonvulsant activity
bipolar disorder
blood brain barrier
brain edema
brain ischemia
central nervous system disease
central nervous system tumor
CLogP
digestive system cancer
dose response
drug design
drug efficacy
drug potency
drug receptor binding
drug structure
drug synthesis
excitotoxicity
human
hyperthermia
hypothermia
lipophilicity
low drug dose
neuromodulation
neuroprotection
nonhuman
Parkinson disease
retina disease
review
seizure
spinal cord compression
statistical parameters
structure activity relation
toxicity testing
description Amino acids are well known to be an important class of compounds for the maintenance of body homeostasis and their deficit, even for the polar neuroactive aminoacids, can be controlled by supplementation. However, for the amino acid taurine (2-aminoethanesulfonic acid) this is not true. Due its special physicochemical properties, taurine is unable to cross the blood-brain barrier. In addition of injured taurine transport systems under pathological conditions, CNS supplementation of taurine is almost null. Taurine is a potent antioxidant and anti-inflammatory semi-essential amino acid extensively involved in neurological activities, acting as neurotrophic factor, binding to GABA A/glycine receptors and blocking the excitotoxicity glutamate-induced pathway leading to be a neuroprotective effect and neuromodulation. Taurine deficits have been implicated in several CNS diseases, such as Alzheimer's, Parkinson's, epilepsy and in the damage of retinal neurons. This review describes the CNS physiological functions of taurine and the development of new derivatives based on its structure useful in CNS disease treatment.&; 2012 by the authors; licensee MDPI, Basel, Switzerland.
publishDate 2012
dc.date.none.fl_str_mv 2012-10-23
2014-05-27T11:27:06Z
2014-05-27T11:27:06Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.3390/ph5101128
Pharmaceuticals, v. 5, n. 10, p. 1128-1146, 2012.
1424-8247
http://hdl.handle.net/11449/73673
10.3390/ph5101128
2-s2.0-84869206693
2-s2.0-84869206693.pdf
9734333607975413
0000-0003-4141-0455
url http://dx.doi.org/10.3390/ph5101128
http://hdl.handle.net/11449/73673
identifier_str_mv Pharmaceuticals, v. 5, n. 10, p. 1128-1146, 2012.
1424-8247
10.3390/ph5101128
2-s2.0-84869206693
2-s2.0-84869206693.pdf
9734333607975413
0000-0003-4141-0455
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Pharmaceuticals
1,293
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 1128-1146
application/pdf
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1799964575344361472